European Disease Registry on Retinopathy of Prematurity (ROP)
Launched by UNIVERSITY MEDICINE GREIFSWALD · Jun 16, 2021
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The European Disease Registry on Retinopathy of Prematurity (ROP) is a study aimed at gathering information about infants who have been treated for a condition called Retinopathy of Prematurity. This condition affects the eyes of premature babies, and the registry will collect routine medical data from hospitals across Europe without conducting any extra tests or treatments. The goal is to understand how severe cases of ROP typically look, how they change over time, and the different treatment methods used in various countries.
Infants who are being treated for ROP according to national guidelines may be eligible to participate in this registry. Parents or guardians must provide consent for their child’s information to be documented and stored. By joining this study, participants will help researchers learn more about the disease and its treatment, which could improve care for future patients. There are no specific time limits on how long the registry will run, and it is open to as many hospitals and patients as possible.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ROP requiring treatment according to the respective national ROP screening and treatment guidelines
- Exclusion Criteria:
- • Denial or absence of consent for documentation and electronic storage of personal data by parents or legal guardians
About University Medicine Greifswald
University Medicine Greifswald is a prominent academic medical center located in Greifswald, Germany, dedicated to advancing healthcare through innovative research and clinical excellence. As a clinical trial sponsor, it fosters a collaborative environment that integrates cutting-edge scientific inquiry with patient care, focusing on a wide range of medical disciplines. The institution is committed to enhancing patient outcomes by conducting rigorous clinical trials that adhere to the highest ethical standards and regulatory requirements. With a strong emphasis on interdisciplinary collaboration, University Medicine Greifswald aims to contribute significantly to the development of new therapies and medical advancements, ultimately improving healthcare delivery and patient well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Bydgoszcz, , Poland
Pristina, , Kosovo
Sofia, , Bulgaria
Ulm, , Germany
Ordu, , Turkey
Thessaloníki, , Greece
Poznań, , Poland
Aachen, , Germany
Berlin, , Germany
Berlin, , Germany
Chemnitz, , Germany
Cologne, , Germany
Düsseldorf, , Germany
Freiburg, , Germany
Greifswald, , Germany
Göttingen, , Germany
Hamburg, , Germany
Lübeck, , Germany
Münster, , Germany
Regensburg, , Germany
Tübingen, , Germany
Salzburg, , Austria
Sofia, , Bulgaria
Tartu, , Estonia
Paris, , France
Bonn, , Germany
Cottbus, , Germany
Cottbus, , Germany
Fulda, , Germany
Gießen, , Germany
Hannover, , Germany
Munich, , Germany
Potsdam, , Germany
Białystok, , Poland
Valencia, , Spain
Geneva, , Switzerland
Adana, , Turkey
Ankara, , Turkey
Ankara, , Turkey
Ankara, , Turkey
Ankara, , Turkey
Ankara, , Turkey
Bursa, , Turkey
Istanbul, , Turkey
Samsun, , Turkey
Kiev, , Ukraine
Kiev, , Ukraine
Odesa, , Ukraine
Plovdiv, , Bulgaria
Braunschweig, , Germany
Ludwigshafen, , Germany
Münster, , Germany
Nuremberg, , Germany
Athens, , Greece
Larissa, , Greece
Katowice, , Poland
Olsztyn, , Poland
Málaga, , Spain
Istanbul, , Turkey
Patients applied
Trial Officials
Andreas Stahl, Professor
Principal Investigator
Department of Ophthalmology, University Medicine Greifswald
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials